[ad_1]
With a patent protected stem cell marker technology and its own production facility, Xintela is a player to be reckoned with in the field of cell therapy. Now they are also investing in the development of a new treatment method for aggressive breast cancer.
Xintela develops treatments in areas where the need for new innovations is great: osteoarthritis, covid-19 and aggressive cancers. The development work is based on the company’s Xinmark marker technology, where specific cell surface proteins function as target molecules in stem cells and cancer cells.
From the beginning, Xintela has focused on stem cell therapy for osteoarthritis patients. Through preclinical studies in horses, the company has shown that stem cells produced with the help of the marker can slow the development of osteoarthritis in horses after joint cartilage damage.
EXTERNAL LINK: Invitation to the Xintela edition
Unique marker technology
– We are not the only ones working with stem cells, but our technology really makes us unique. With our markers, we can separate stem cells from, for example, adipose tissue and produce a high-quality, homogeneous stem cell preparation, which is then expanded in large quantities, says Evy Lundgren-Åkerlund, CEO of Xintela.
Xintela has its own GMP-ready production facility to manufacture its stem cell products for clinical trials. The company is now awaiting a permit to produce the first Xstem-Oa product and begin clinical trials in osteoarthritis patients.
Xinmark marker technology can also be used to detect certain aggressive cancer cells and the treatment antibodies directed at them. Xintela has previously focused on aggressive brain tumor glioblastoma, and recently the company announced that the next area of focus will be triple negative breast cancer, also a very aggressive form of cancer with a poor prognosis.
New indications meet great medical needs
– The Xinmark platform gives us the opportunity to expand our operations to new areas of development. Therefore, we have now added the triple aggressive breast cancer and also started a preclinical study of our stem cells as a treatment for acute respiratory distress syndrome (ARDS), a serious lung complication that affects some patients with covid-19, says Evy Lundgren-Åkerlund.
He now hopes to achieve collaborations with strategic partners within the company’s business areas to further strengthen Xintela’s place in the market.
EXTERNAL LINK: Read more about Xintela’s investment in a new treatment for aggressive breast cancer
Fakta Xintela
Xintela is a biomedical company active in regenerative medicine and cancer. With its patent-protected marker technology, the company is developing new treatment methods for, for example, osteoarthritis and brain tumors. www.xintela.se
